Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Batch Records

Analytics Overview

88
Form 483s Issued
11
483s converted to WL
111
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
25 Oct 2024
OSRX Inc.
Drugs
27 Sep 2024
Biocon Sdn Bhd
Drugs
20 Sep 2024
Aarti Drugs Limited
Drugs
06 Sep 2024
Annovex Pharma, Inc.
Drugs
29 Aug 2024
Zydus Lifesciences Limited
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
17
3
Pratik S Upadhyay
8
2
Anastasia M Shields
8
1
Nibin Varghese
5
0
Camerson E Moore
4
0
TITLE/ COMPANY Issue Date Status Details
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements
OSRX Inc.
25 Oct 2024 Normal Justification: The issue directly relates to the integrity and completeness of batch records prior to product release.
Excerpt: your firm performed an early release of drug product...without the sterility testing being completed...
View Details
The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing, processing, and packing.
Biocon Sdn Bhd
27 Sep 2024 Normal Justification: Batch Records are linked to the observation due to missing documentation of essential production steps, critical for traceability.
Excerpt: Batch records do not include documentation of the accomplishment of each significant step. No system to link finger dab results.
View Details
Records associated with the API distribution were not readily available
Aarti Drugs Limited
20 Sep 2024 Normal Justification: Missing batch numbers and overlooked suffixes demonstrate flawed batch record maintenance and control.
Excerpt: The corresponding Batch No. (Mfg. date (b) (4) June 2022 Expiry date was missing from the initial list submitted.
View Details
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications.
Granules India Limited
06 Sep 2024 Normal Justification: Observation highlights discrepancies in batch handling and documentation, falling under the batch records process.
Excerpt: Your firm dispatched the failing batch # (3rd PV batch) along with batches # 1st PV (b) (4) (b).
View Details
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch
Annovex Pharma, Inc.
06 Sep 2024 Normal Justification: Batch Records process is pivotal as discrepancies in batch records directly impact product quality.
Excerpt: the failure of a batch or any of its components to meet any of its specifications.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.